Breast cancer vaccine:
Breast cancer is a cancer that starts in
the tissues of the breast.
There are two main types of breast
Ductal carcinoma starts in the tubes
(ducts) that move milk from the breast
to the nipple. Most breast cancers are
of this type.
Lobular carcinoma starts in parts of
the breast, called lobules, that produce
STIMUVAX CANCER VACCINE FOR
BREAST TUMOR PATIENTS
by Merck KGaA. Stimuvax is an
innovative cancer vaccine designed to
induce an immune response to cancer
cells that express MUC1, a protein
antigen widely expressed on common
cancers. MUC1 is over expressed on
many cancers such as lung cancer,
breast cancer, prostate cancer and
Stimuvax is being developed by Merck
KGaA of Darmstadt, Germany under a
license agreement with Oncothyreon.
Merck is currently conducting three
Phase 3 trials of Stimuvax.
Additional breast cancer vaccines are
being developed against other
probable targets, such as human
epidermal growth factor receptor 2, or
HER-2. This growth factor, produced in
abnormally high levels in 20-25
percent of breast cancers, is already a
target of breast cancer drugs
Trastuzumab and Lapatinib.
Trials of a vaccine to prevent breast
cancer could begin next year.
The injection targets a protein called
alpha-lactalbumin, which is found in
breast tumors, and Dr Vincent Tuohy,
the man who developed it, believes it
will stop 70 per cent of cancers.